Arrowhead Pharmaceuticals Inc

NASDAQ:ARWRUnited States

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.

Contact Information

Headquarters

177 E Colorado Blvd, Suite 700PASADENA, CA, United States 91105

Phone

626-696-4702

Fax

626-304-3401

Executives

Independent Chairman of the Board

Douglass Given

President, Chief Executive Officer, Director

Christopher Anzalone

Chief Financial Officer

Kenneth Myszkowski

Chief Operating Officer, General Counsel, Company Secretary

Patrick O'Brien

Chief of Discovery and Translational Medicine

James Hamilton